LARGE B-CELL LYMPHOMA

This study tests whether a personalized cell therapy called liso-cel can stop large B-cell lymphoma from returning in patients who still have traces of cancer DNA after initial treatment. About 50 adults who are in remission but test positive for lymphoma DNA will receive their o…

This early-stage trial tests whether giving radiation therapy and the antibiotic vancomycin before CAR-T cell therapy is safe and doable for people with large B-cell lymphoma. About 14 adults whose lymphoma has not responded or has come back will receive this combination. The goa…

This phase 3 trial investigates whether adding the targeted drug acalabrutinib to a reduced-dose chemotherapy regimen (R-miniCHOP) helps older adults with untreated diffuse large B-cell lymphoma live longer without their cancer progressing. Participants are randomly assigned to r…

This study tests a new cell therapy called cemacabtagene ansegedleucel (cema-cel) in adults with large B-cell lymphoma who still have tiny amounts of cancer cells (minimal residual disease) after finishing their first standard treatment. About 250 participants will be randomly as…

This study tests whether older or frail adults newly diagnosed with large B-cell lymphoma can get just 2 rounds of chemo (R-mini-CHOP) followed by a new drug called AZD0486, instead of the usual 6 rounds of chemo. The goal is to see if the shorter chemo-plus-new-drug approach wor…

This phase 2 trial is testing a combination of two immune-based therapies—axicabtagene ciloleucel (a CAR T-cell therapy) and glofitamab (a bispecific antibody)—in 40 people with large B cell lymphoma that has relapsed or not responded to first treatment. The goal is to see if the…

This program offers Yescarta, a CAR T-cell therapy, to adults with large B-cell or follicular lymphoma whose manufactured batch didn't meet commercial standards but still meets clinical trial criteria. Participants receive a single infusion, and the goal is to provide access when…

This study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This study tests whether a combination of two drugs, zanubrutinib and tislelizumab, along with standard care, can help people with large B-cell lymphoma whose cancer got worse after CAR-T cell therapy. About 76 adults will take part. The goal is to see if the treatment can shrink…

This early-stage trial is testing whether giving radiation therapy before a bispecific antibody drug (either epcoritamab or glofitamab) is safe and feasible for people with relapsed or refractory diffuse large B-cell lymphoma. The study will enroll 12 adults who have already trie…

This study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and…

This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…

This study tests a new treatment called rondecabtagene autoleucel (ronde-cel) for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. Ronde-cel is a CAR T-cell therapy that targets two proteins (CD19 and CD20) on cancer cells. …

This study tests whether giving additional antibody drugs (mosunetuzumab or glofitamab plus obinutuzumab) after CAR-T cell therapy can improve outcomes for people with relapsed or refractory large B-cell lymphoma. About 23 participants will receive the combination to see if it le…

This phase 2 trial is testing whether the drug loncastuximab tesirine (Lonca) can help patients with large B-cell lymphoma who had only a partial response after CAR T-cell therapy achieve a complete remission. About 30 adults will receive Lonca as a consolidation treatment. The s…

This phase 2 trial is testing whether adding the drug epcoritamab to a standard chemotherapy combination (R-miniCVP) can better control newly diagnosed diffuse large B-cell lymphoma in older or frail patients who cannot take strong chemotherapy. The study will enroll 40 adults an…

This early-phase study tests a new treatment called JV-213 for adults with B-cell lymphoma that has come back or not responded to other treatments. JV-213 uses the patient's own immune cells, modified to attack cancer cells. The main goal is to find the safest dose and monitor si…

This early-phase trial tests whether adding a drug called NT-I7 after standard CAR T-cell therapy can help the immune cells work better and last longer in people with relapsed or refractory large B-cell lymphoma. About 24 participants will receive NT-I7 after their CAR T treatmen…

This early-phase trial is testing whether adding a patient's own blood stem cells to standard CAR T-cell therapy is safe and doable for people with relapsed or refractory blood cancers like lymphoma, leukemia, and myeloma. Twenty participants will receive their own stem cells 10 …

This study tests an experimental drug called AZD5492 in people with B-cell cancers (like lymphoma or leukemia) that have come back or not responded to at least two prior treatments. The drug works by helping the body's T cells attack cancer cells. The trial will check safety, sid…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This phase 2 study tests whether the drugs tafasitamab and lenalidomide can shrink or eliminate large B-cell lymphoma that remains after treatment with CAR-T therapy (axicabtagene ciloleucel). About 28 adults with this type of lymphoma will receive the drug combination for up to …

This early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…

This study tests whether giving focused radiation to large tumors before CAR-T cell therapy can help control aggressive large B-cell lymphoma that has come back or not responded to treatment. About 27 adults with tumors at least 5 cm will receive this combination. The goal is to …

This study tests whether the drug acalabrutinib, taken as a pill, can safely prevent relapse in people with very high-risk large B-cell lymphoma after they receive cell therapy (stem cell transplant or CAR T-cells). The trial will enroll 24 adults aged 18-70. Researchers will tra…

This phase 2 trial is testing a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard treatment. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will measure …

This phase 2 study is testing whether combining two drugs—epcoritamab and loncastuximab tesirine—can safely shrink or eliminate lymphoma in people whose large B-cell lymphoma has come back or not responded to treatment. About 26 adults will receive the drugs over several cycles. …

This study tests whether a ketone supplement (beta-hydroxybutyrate) is safe and tolerable for 5 adults with large B-cell lymphoma who are receiving standard CAR-T cell therapy. Researchers will also look at changes in gut bacteria and immune cells. The supplement is given as a dr…

This early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called …

This program provides access to a CAR-T cell therapy called lisocabtagene maraleucel (liso-cel) that didn't meet all commercial quality standards. It is for adults with large B-cell lymphoma who were already prescribed liso-cel as part of their care. Patients receive chemotherapy…

This study tests whether the drug maribavir can safely control cytomegalovirus (CMV) infections in people with multiple myeloma or lymphoma who are receiving bispecific antibody therapy. About 20 adults will take maribavir, and researchers will measure how well it lowers CMV leve…

This phase 2 trial tests a combination of three drugs—glofitamab, a PD-1 inhibitor, and lenalidomide—in 24 adults with relapsed or refractory large B-cell lymphoma that has a TP53 gene mutation. The goal is to see if this mix can shrink tumors or make them disappear. The study is…

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This phase 2 trial tests whether emapalumab, a drug that blocks a protein called interferon gamma, can prevent severe cytokine release syndrome (CRS) in patients receiving CAR-T cell therapy for certain types of non-Hodgkin lymphoma. About 28 adults with relapsed or refractory la…

This early-phase trial is testing whether a second infusion of the CAR T-cell therapy Axi-Cel (called Axi-Cel-2) is safe for people with high-risk large B-cell lymphoma whose cancer came back after standard CAR T treatment. About 20 adults will receive the second infusion and be …

This early-stage study is testing a new gene therapy called UB-VV400, alone and with the drug rapamycin, in 70 adults with relapsed or refractory large B-cell lymphoma. The main goals are to find safe doses and check for side effects. Researchers will also look for signs that the…

This study looks back at medical records of about 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. The goal is to see how well the drug works and what side effects occur in everyday practice, especially in patients…

This study is collecting information and samples from 800 people with large B-cell lymphoma who are either too frail for standard treatment or have not responded to initial therapy. The goal is to understand how these patients are managed and what outcomes they have, which could …

This study aims to find out which factors help predict whether CAR-T therapy will work in people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient health records, tumor features, and immune system changes in 80 participants. The goal is to better…

This study is testing a new communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors better discuss the diagnosis and plan future care with their patients. About 48 people (doctors and patients) will take part to…